Multimorbidity Management Supported by a Digital Platform
ConditionChronic Disease
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age50+
SponsorUniversidade Nova de Lisboa
About this trial
This study aims to assess whether the use of the METHIS digital platform using a patient-centered approach contributes to an improvement in the quality of life, mental health and physical activity of patients with multimorbidity followed up in Primary Health Care. Practices will be randomly allocated between: providing access to consultations through the METHIS platform (intervention) or following patients by the traditional method (control). They will complete questionnaires on quality of life, mental health and report the number of steps taken, at the beginning and end of the study.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
community-dwelling people
aged 50 or older
with complex multimorbidity (co-occurrence of three or more chronic conditions affecting three or more different body systems)
with access to an Internet connection and a communication technology device
Disqualifiers
inability to: provide informed consent, to read or write, inability to access an email or electronic device, even when helped by an informal caregiver
Trial design
Design model
Parallel
Treatments tested in this trial
METHIS Platform
DeviceThe METHIS platform is a digital healthcare platform, supported by three databases using PostreSQL (based in relational SQL). One of the databases allows adequate internal testing before production. Another database of production (secured with unique access codes) will be created to retrieve data from the practices' and the last database for the research data, where pseudonymised production data can be analysed for research purposes. The platform is integrated (via FCCN Scientific Computation Unit of the Portuguese Fundação para a Ciência e a Tecnologia) with the Software Zoom® to allow encrypted teleconsultations, with a guarantee that each patient connection is unique. The digital platform is web-based, and it can be used in multiple devices.
Goal-Oriented Care Training Program
Other interventionThe training program will have three stages: initial face-to-face training, which will happen before the data collection, followed by remote, asynchronous training during a 12-month period, and a final seminar to discuss the results and inquire about the usability of the GOC model and the METHIS platform. The course will be offered to the intervention group one month before the start of patient recruitment, and for the control group at least one month after the end of data collection.
Treatment groups
1,380 Participants
are divided into 2 treatment groupsGroup A: METHIS InterventionExperimental treatment 2 interventions
Group B: ControlNo intervention 0 interventions
Trial outcomes
Primary outcomes
1
Health related quality of life
Participants will be asked to fill in the SF-12 questionnaire which generates a physical component score (PCS) and a mental component score (MCS). The primary outcome will be the mean difference in the variation (delta) of the PCS of SF-12 between baseline and 12 months. The SF-12 can be filled in 2-4 minutes, and it is validated for the Portuguese population. Minimum important differences validated across large populations and multiple disease categories are a change in between 2 and 3 points from the population mean of 50.
Time frame
Participants will be asked to fill in the SF-12 questionnaire at baseline and at 12 months.Secondary outcomes
1
Mental health status
Participants will be asked to complete the Hospital Anxiety and Depression Scale questionnaire (HADS-A and HADS-D, respectively). The investigators will calculate the mean difference in the variation (delta) in HADS-A and HADS-D between baseline and 12 months. Although HADS was designed for inpatients it was posteriorly validated in the primary care outpatient setting. A minimum important difference of 1.5 has been reported in other chronic disorders.
Time frame
Participants will complete the HADS-A and HADS-D questionnaire at baseline and at 12 months.2
Physical activity
Physical activity will be monitored through the number of steps walked daily. To assess the number of steps per day, a smart band with a triaxial Accelerometer will be used in both arms of the trial. Although traditional step counters use pedometers to detect daily step counts, accelerometers are more accurate and sensitive to lower force accelerations (e.g., slow walking) being considered the current standard for collecting physical activity data. Sedentary older adults and individuals living with disability and chronic illness benefit from a physically active lifestyle, with approximately 4,600- 5,500 daily steps. The lowest median values for steps/day found is in disabled older adults (1214 steps/day) and by people living with COPD (2237 steps/day).
Time frame
Participants will wear the SmartBand for 12 months.3
Number of serious adverse events (clinician-reported)
These will be the safety outcomes chosen for this trial. In both trial arms, data about patient mortality will be collected and combined with data on occurrence of emergency department visits and hospital admissions as a proxy for serious adverse events. This information is available through the Portuguese common EHR. Due to legal requirements, after death, the information about hospital admissions and other contacts with healthcare organisations ceases to be available to the attending physician.
Time frame
Family physicians will be asked, at 6 and 12 months after randomization, to check the life status of enrolled patients and whether patients in the trial were admitted to a hospital or had a visit to an emergency service since the randomization date.4
Number of potentially missed diagnoses (clinician-reported)
These will be a second safety outcome. The investigators will ask clinicians in the intervention arm if they are aware of any serious diagnosis that might have been missed due to the intervention.
Time frame
Potentially missed diagnoses will be reported 6 months after the intervention phase. In this way a compromise between avoiding recall bias and allowing enough time for a missed diagnosis to become clinically apparent is achieved.Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Universidade Nova de Lisboa
Lead sponsor
Administração Regional de Saúde de Lisboa e Vale do Tejo, Portugal
Collaborator
Universidade Lusófona de Humanidades e Tecnologias
Collaborator
NOVA Medical School
Collaborator
NOVA School of Science and Technology ı FCT NOVA
Collaborator
University Hospital, Geneva
Collaborator
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: